Skip to main content

RoosterBio

MaterialsFrederick, MD, USAFounded 2013· One of 961 Materials companies tracked by AMPulse

Supplies high-volume, well-characterized adult human mesenchymal stem cells (hMSCs) and engineered media systems for bioprinting and regenerative medicine, reducing cell costs from >$1,000 to <$10 per million cells.

CEO / Founder
Tim Kelly
Team Size
51-200
Stage
Active
Total Funding
$41.6M
Latest Round
Series C
Key Investors
BroadOak Capital Partners, Dynamk Capital, Maryland Stem Cell Research Fund (MSCRF), Planetary Technologies

Technology & Products

Key Products

RoosterRTP™-hBM-50M-XF (Ready-to-Print stem cells); hMSC bioprocessing systems; Bioprocess media systems; Genetic engineering tools; Extracellular vesicle (EV) production solutions; cGMP-compatible products like RoosterGEM™

Technological Advantage

Proprietary scalable biomanufacturing platforms for hMSCs and EVs, with chemically defined, xeno-free media systems that achieve high cell viability and consistency, supported by process development expertise and regulatory experience.

Differentiation

Value Proposition

Accelerates bioprinting and cell therapy development by providing standardized, scalable hMSC systems that cut weeks from the cellular bioprinting process, enabling faster clinical translation and reducing costs by over 99% per million cells.

How They Differentiate

Offers the first commercial Ready-to-Print stem cell products specifically for bioprinting, with standardized, scalable hMSC systems that reduce costs by over 99% per million cells compared to traditional sources, unlike competitors focused on general cell culture media or bioprinting hardware.

Market & Competition

Target Customers

Advanced therapy product developers and manufacturers in pharma and biotech, academic and government researchers in regenerative medicine, tissue engineering, and 3D bioprinting.

Industry Verticals

Regenerative Medicine; Cell Therapy; Tissue Engineering; Bioprinting; Biotechnology

Competitors

STEMCELL Technologies, CellGenix, AskBio

Growth & Milestones

Growth Metrics

Revenue ~$8.9M annually; serves 200–500+ global customers; team size ~60 employees.

Major Milestones

Founded in 2013; Launched first Ready-to-Print stem cell product in 2015; Raised $15M Series B in 2019 led by Dynamk Capital; Launched RoosterGEM™ cGMP-compatible product in 2021; Raised $12M Series C in 2024

Notable Customers

Large pharmaceutical companies, small start-ups, translational centers, AGC Biologics, Thermo Fisher Scientific, Portal Biotechnologies

https://www.roosterbio.com

Why this company matters

RoosterBio occupies a distinct position at the intersection of bioprinting and cell therapy by offering standardized, scalable adult human mesenchymal stem cell (hMSC) systems. Its core value proposition is reducing the cost of hMSCs from over $1,000 to under $10 per million cells, a reduction of more than 99%, while cutting weeks from the cellular bioprinting workflow. This addresses a critical bottleneck in translating bioprinted tissues and cell therapies from research to clinical use.

The company's flagship product, RoosterRTP™-hBM-50M-XF, is marketed as the first commercial Ready-to-Print stem cell product specifically designed for bioprinters. RoosterBio also provides bioprocess media systems, genetic engineering tools, and extracellular vesicle (EV) production solutions, including cGMP-compatible products like RoosterGEM™. Its proprietary biomanufacturing platforms use chemically defined, xeno-free media to achieve high cell viability and consistency, supported by process development expertise and regulatory experience.

Target customers include advanced therapy product developers in pharma and biotech, as well as academic and government researchers in regenerative medicine, tissue engineering, and 3D bioprinting. Named partners include AGC Biologics, Thermo Fisher Scientific, Portal Biotechnologies, CELLINK (for living cellular bioink kits), FUJIFILM Diosynth Biotechnologies, Repligen, and Nikon CeLL Innovation. The company has raised $41.6M from investors including BroadOak Capital Partners and Dynamk Capital, and reports annual revenue of approximately $8.9M with 200–500+ global customers.

RoosterBio's strategic moat lies in its first-mover position with Ready-to-Print stem cells for bioprinting and its cost reduction model that makes hMSCs accessible at industrial scale. Competitive risk comes from general cell culture media suppliers like STEMCELL Technologies and CellGenix, as well as bioprinting hardware companies that may develop their own cell sources. The company's expansion into the Chinese market and partnerships with GMP manufacturers suggest a focus on bridging the gap between ideation and commercialization for advanced therapy startups.